Foghorn Therapeutics (NASDAQ:FHTX), Inc. is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines that target chromatin regulatory mechanisms. By leveraging insights into how chromatin structure and function govern gene expression, Foghorn seeks to address underlying drivers of cancer and rare genetic diseases. The company’s approach centers on understanding the interplay between chromatin-associated proteins and the genome to design novel small molecules and biologics capable of modulating cellular identity and behavior.
The company’s proprietary Chromatin Biology Platform integrates high-throughput screening, structural biology, and cellular profiling to identify epigenetic regulators with therapeutic potential. Its lead oncology programs are advancing through early-stage clinical trials, targeting specific chromatin modifiers implicated in hematologic malignancies and solid tumors. In parallel, Foghorn is exploring collaborations to expand its pipeline into other disease areas where dysregulated chromatin dynamics play a central role.
Founded in 2015 by a team of scientists and investors including Atlas Venture and Flagship Pioneering, Foghorn completed its initial public offering in 2020 and trades on the NASDAQ under the ticker symbol FHTX. The company maintains research operations in North America and Europe, and has entered into strategic partnerships with established pharmaceutical organizations to accelerate the development of its drug candidates. These alliances provide access to complementary expertise, resources, and target discovery capabilities.
Foghorn’s leadership team is composed of seasoned professionals from the biotech and pharmaceutical industries, including experts in epigenetics, oncology drug development, and translational research. Under the direction of its Chief Executive Officer, Vikram Sheel Kumar, the company continues to advance its mission of delivering first-in-class and best-in-class chromatin-targeted therapies to patients in need.
